Published in Psychopharmacologia on January 01, 1975
The pharmacokinetics of metoclopramide in man with observations in the dog. Br J Clin Pharmacol (1980) 1.40
Tardive dyskinesia associated with metoclopramide. Br Med J (1978) 1.33
Dopaminergic inhibition of metoclopramide-induced aldosterone secretion in man. Dissociation of responses to dopamine and bromocriptine. J Clin Invest (1980) 1.03
Comparative studies on the effects of metoclopramide and some known neuroleptics on the EEG of the conscious rat [proceedings]. Br J Pharmacol (1976) 0.96
Anti-dopaminergic effect of the methanolic extract of Morus alba L. leaves. Indian J Pharmacol (2008) 0.90
Proceedings: Is metoclopramide a directly acting dopamine receptor antagonist? Br J Pharmacol (1976) 0.84
Effect of metoclopramide in guinea-pig ileum longitudinal muscle: evidence against dopamine-mediation. Gut (1982) 0.81
Apomorphine in idiopathic restless legs syndrome: an exploratory study. J Neurol Neurosurg Psychiatry (2005) 0.75
Substituted benzamides as dopamine antagonists [proceedings]. Br J Pharmacol (1976) 0.75
Pituitary secretion after administration of a new cerebroactive drug, fipexide. Br J Clin Pharmacol (1984) 0.75
Corticocortical inhibition in human motor cortex. J Physiol (1993) 8.92
Mitochondrial complex I deficiency in Parkinson's disease. Lancet (1989) 5.72
Electric and magnetic stimulation of human motor cortex: surface EMG and single motor unit responses. J Physiol (1989) 5.69
Servo action in the human thumb. J Physiol (1976) 4.93
Interhemispheric inhibition of the human motor cortex. J Physiol (1992) 4.77
Servo action in human voluntary movement. Nature (1972) 4.33
Mitochondrial complex I deficiency in Parkinson's disease. J Neurochem (1990) 4.03
Painful legs and moving toes. Brain (1971) 3.63
Validity and reliability of a rating scale for the primary torsion dystonias. Neurology (1985) 3.56
The behavioural and motor consequences of focal lesions of the basal ganglia in man. Brain (1994) 3.54
Writers' cramp-a focal dystonia. Brain (1982) 3.43
Slater revisited: 6 year follow up study of patients with medically unexplained motor symptoms. BMJ (1998) 3.41
Outcome of investigation of patients with presenile dementia. Br Med J (1972) 3.39
Grafts of fetal dopamine neurons survive and improve motor function in Parkinson's disease. Science (1990) 3.31
Stretch reflex and servo action in a variety of human muscles. J Physiol (1976) 3.29
Scope of a technique for electrical stimulation of human brain, spinal cord, and muscle. Lancet (1982) 3.26
The mysterious motor function of the basal ganglia: the Robert Wartenberg Lecture. Neurology (1982) 3.26
Corticobasal degeneration. Brain (1989) 3.20
Stimulation of the human motor cortex through the scalp. Exp Physiol (1991) 3.16
Peripheral beta-adrenergic receptors concerned with tremor. Clin Sci (1967) 2.97
The pathophysiology of extrapyramidal side-effects of neuroleptic drugs. Psychol Med (1980) 2.81
Motor cortex stimulation in intact man. 2. Multiple descending volleys. Brain (1987) 2.77
Positron emission tomography studies on the dopaminergic system and striatal opioid binding in the olivopontocerebellar atrophy variant of multiple system atrophy. Ann Neurol (1995) 2.76
Classification of dystonia. Adv Neurol (1998) 2.75
Botulinum toxin in spasmodic torticollis. J Neurol Neurosurg Psychiatry (1988) 2.74
Blepharospasm-oromandibular dystonia syndrome (Brueghel's syndrome). A variant of adult-onset torsion dystonia? J Neurol Neurosurg Psychiatry (1976) 2.72
Human walking and higher-level gait disorders, particularly in the elderly. Neurology (1993) 2.65
Alterations in glutathione levels in Parkinson's disease and other neurodegenerative disorders affecting basal ganglia. Ann Neurol (1994) 2.65
Fronto-striatal cognitive deficits at different stages of Parkinson's disease. Brain (1992) 2.64
Manual motor performance in a deafferented man. Brain (1982) 2.63
The anatomical basis of symptomatic hemidystonia. Brain (1985) 2.60
Is the human stretch reflex cortical rather than spinal? Lancet (1973) 2.58
"On-off" effects in patients with Parkinson's disease on chronic levodopa therapy. Lancet (1976) 2.54
Movement disorders in multiple sclerosis. Mov Disord (1995) 2.53
Alterations in the levels of iron, ferritin and other trace metals in Parkinson's disease and other neurodegenerative diseases affecting the basal ganglia. Brain (1991) 2.52
The pathophysiology of primary dystonia. Brain (1998) 2.51
Pathophysiology of blepharospasm and oromandibular dystonia. Brain (1985) 2.50
A method of monitoring function in corticospinal pathways during scoliosis surgery with a note on motor conduction velocities. J Neurol Neurosurg Psychiatry (1986) 2.50
Blepharospasm: a review of 264 patients. J Neurol Neurosurg Psychiatry (1988) 2.46
Differing patterns of striatal 18F-dopa uptake in Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy. Ann Neurol (1990) 2.45
Changes in the response to magnetic and electrical stimulation of the motor cortex following muscle stretch in man. J Physiol (1991) 2.44
Increased nigral iron content and alterations in other metal ions occurring in brain in Parkinson's disease. J Neurochem (1989) 2.44
Attitudes of families to some aspects of Huntington's chorea. Psychol Med (1979) 2.40
A study of hereditary essential tremor. Brain (1994) 2.37
Focal dystonia of the jaw and the differential diagnosis of unilateral jaw and masticatory spasm. J Neurol Neurosurg Psychiatry (1986) 2.37
'Frontal' cognitive function in patients with Parkinson's disease 'on' and 'off' levodopa. Brain (1988) 2.36
Isolated tremor and disruption of the nigrostriatal dopaminergic system: an 18F-dopa PET study. Neurology (1992) 2.36
Disturbance of sequential movements in patients with Parkinson's disease. Brain (1987) 2.30
Abnormalities in central motor pathway conduction in multiple sclerosis. Lancet (1984) 2.30
Postural electromyographic responses in the arm and leg following galvanic vestibular stimulation in man. Exp Brain Res (1993) 2.30
Isolated single motor units in human muscle and their rate of discharge during maximal voluntary effort. J Physiol (1971) 2.28
Basal lipid peroxidation in substantia nigra is increased in Parkinson's disease. J Neurochem (1989) 2.26
Review of 23 patients affected by the stiff man syndrome: clinical subdivision into stiff trunk (man) syndrome, stiff limb syndrome, and progressive encephalomyelitis with rigidity. J Neurol Neurosurg Psychiatry (1998) 2.22
Delay in the execution of voluntary movement by electrical or magnetic brain stimulation in intact man. Evidence for the storage of motor programs in the brain. Brain (1989) 2.19
The sensory mechanism of servo action in human muscle. J Physiol (1977) 2.18
Anticonvulsant-induced dyskinesias: a comparison with dyskinesias induced by neuroleptics. J Neurol Neurosurg Psychiatry (1976) 2.18
Association of slow acetylator genotype for N-acetyltransferase 2 with familial Parkinson's disease. Lancet (1997) 2.16
Hysteria--a neurologist's view. Psychol Med (1986) 2.12
Oxidative DNA damage in the parkinsonian brain: an apparent selective increase in 8-hydroxyguanine levels in substantia nigra. J Neurochem (1997) 2.10
Corticobasal degeneration. A clinical study of 36 cases. Brain (1994) 2.10
'Subcortical dementia': the neuropsychological evidence. Neuroscience (1988) 2.08
Autosomal dominant nocturnal frontal lobe epilepsy. A distinctive clinical disorder. Brain (1995) 2.06
Ballistic flexion movements of the human thumb. J Physiol (1979) 2.06
Disruption of spatial organization and interjoint coordination in Parkinson's disease, progressive supranuclear palsy, and multiple system atrophy. Mov Disord (2000) 2.06
Reciprocal inhibition between the muscles of the human forearm. J Physiol (1984) 2.05
Relationship between plasma propranolol concentration and relief of essential tremor. J Neurol Neurosurg Psychiatry (1979) 2.04
Failure of the ubiquitin-proteasome system in Parkinson's disease. Nat Rev Neurosci (2001) 2.04
Teaching tape for the motor section of the unified Parkinson's disease rating scale. Mov Disord (1995) 2.03
Modulation of motor cortical excitability by electrical stimulation over the cerebellum in man. J Physiol (1991) 2.01
Tissue pH as an indicator of mRNA preservation in human post-mortem brain. Brain Res Mol Brain Res (1995) 1.98
Motor cortex stimulation in intact man. 1. General characteristics of EMG responses in different muscles. Brain (1987) 1.98
Success and problems of long-term levodopa therapy in Parkinson's disease. Lancet (1977) 1.96
Autosomal dominant frontal epilepsy misdiagnosed as sleep disorder. Lancet (1994) 1.95
Performance of simultaneous movements in patients with Parkinson's disease. Brain (1986) 1.95
Idiopathic torsion dystonia (dystonia musculorum deformans). A review of forty-two patients. Brain (1974) 1.93
How common is dementia in Parkinson's disease? Lancet (1984) 1.93
Percutaneous electrical stimulation of corticospinal pathways at the level of the pyramidal decussation in humans. Ann Neurol (1991) 1.93
Assessing tremor severity. J Neurol Neurosurg Psychiatry (1993) 1.92
Effect of vision and stance width on human body motion when standing: implications for afferent control of lateral sway. J Physiol (1993) 1.91
Tardive dystonia: late-onset and persistent dystonia caused by antipsychotic drugs. Neurology (1982) 1.88
Scaling of the size of the first agonist EMG burst during rapid wrist movements in patients with Parkinson's disease. J Neurol Neurosurg Psychiatry (1986) 1.88
Assessment of extrapyramidal disorders. Br J Clin Pharmacol (1981) 1.86
Movement disorders following lesions of the thalamus or subthalamic region. Mov Disord (1994) 1.86
A year's comparison of treatment of patients with parkinson's disease with levodopa combined with carbidopa versus treatment with levodopa alone. Lancet (1973) 1.85
Brain dopamine metabolism in patients with Parkinson's disease measured with positron emission tomography. J Neurol Neurosurg Psychiatry (1986) 1.84
Different sites of action of electrical and magnetic stimulation of the human brain. Neurosci Lett (1987) 1.84
A generalised increase in protein carbonyls in the brain in Parkinson's but not incidental Lewy body disease. J Neurochem (1997) 1.83